Amgen Inc. is seeing a notable increase in its stock price, driven by positive developments in its business strategy and market trends.
Amgen Inc. (NASDAQ:AMGN) is rising today, with shares up by 2.81% to close at CA$404.23. The company is benefiting from a combination of strategic partnerships and favorable market dynamics in the biotechnology sector.
Advertisement
Amgen Inc
AMGN.US
AMGN.US
Amgen Inc
WealthAwesomeMarket cap
$208.49B
P/E
24.0x
Div. yield
2.58%
Div. / share
$9.80
52W high
$447.03
52W low
$262.49
1W change
+3.06%
Beta
0.43
Analyst Price Targets
Based on 32 analysts covering AMGN · as of Sep 21, 2026
Wall Street analysts forecast AMGN stock price to rise 1233.6% over the next 12 months.
Consensus
Buy3.63 / 5.00
Avg. Target
C$387.69
+1233.6% Upside
Previously C$388.03 on Sep 17, 2026
Current Price
C$29.07
Last close
Analyst Breakdown (32 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on AMGN's historical volatility
30-Day Vol
38.4%
Annualized
90-Day Vol
32.9%
Annualized
Trend (90d)
+47.9%
Annualized drift
90d Mean
C$466.54
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$416.24 | C$364.53 – C$475.28 |
| 60 trading days | C$440.67 | C$365.30 – C$531.60 |
| 90 trading days | C$466.54 | C$370.77 – C$587.04 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should consider Amgen's strong position in the growing market for PEGylated proteins and its expanding partnerships, which could enhance its revenue streams and market competitiveness.
Amgen's Stock Up 2.81% Amid Positive Market Developments
The biotechnology sector is experiencing robust growth, particularly in oncology and chronic disease therapies, positioning Amgen favorably for future performance.
Bull case
Amgen's partnership with Veeva Systems to deploy Vault CRM globally is set to improve its commercial operations. This move could lead to greater efficiency and increased revenue. Additionally, the expected growth in the PEGylated proteins market offers Amgen a significant chance to take advantage of new therapies.
Bear case
Despite these positive developments, Amgen faces challenges from rising competition in the biotechnology sector and potential regulatory hurdles that could affect its product pipeline.
Strategic Partnerships Fuel Growth
Advertisement
Amgen's recent decision to expand its partnership with Veeva Systems for global deployment of Vault CRM highlights its commitment to improving operational efficiency. This collaboration aims to streamline Amgen's commercial processes, which could help deliver therapies to market faster and enhance engagement with healthcare professionals.
Market Opportunities in PEGylated Proteins
The global market for PEGylated proteins is projected to grow significantly, reaching US$4.1 billion by 2032. Amgen is well-positioned to take advantage of this trend, as the demand for safer and longer-acting biologics continues to rise. This growth trajectory presents a compelling opportunity for Amgen to expand its product offerings and increase its market share in the biotechnology sector.
Navigating Competitive Challenges
While Amgen's recent gains are promising, the company must navigate a competitive landscape filled with emerging biotech firms and innovations. As the industry evolves, Amgen's ability to maintain its market position will depend on how well it responds to market changes and its capacity to innovate within its therapeutic areas.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
